Tag: ENDV

Reviewing Thursday’s Movers, 4 New Possibilities

Thursday’s Options Recap:

Things ended on a positive note for us on Thursday, just before we broke for the holiday weekend. In our premarket report for the day, we were looking at three potential options trading targets, and everything we came up with produced double-bag intraday runs or better. It’s always nice to end a trading week with a whole slate full of good ideas, and that was certainly the case.

We were considering the SPY 03/28 $522-523 Calls, the MLKN 04/19 $25 Puts, and the RH Weekly $325-330 Calls, and here are the figures those contracts produced on the session:

SPY 03/28 $522-523 Calls
$522: 1.23-2.65 (+115%)
$523: .58-1.71 (+195%)
_____

MLKN 04/19 $25 Puts
$25: .80-1.65 (+106%)
_____

RH Weekly $325-330 Calls
$325: 5.80-28.89 (+398%)
$330: 5.00-23.31 (+366%)

Fresh Options Ideas:
SPY 04/01 $424-425 Calls*
BOIL Weekly $13.50-14.50 Calls
SGML 04/19 $13-14 Calls
LCII 05/17 $120-115 Puts

*Only experienced traders should attempt to trade options on their day of expiration 

Ibio, Inc. (NYSE:IBIO) – Recap:

We mentioned IBIO in our premarket report this past Wednesday the 27th, and the stock responded by finishing out the short week in good form. From the 2.30 low we observed on Wednesday, it went on to hit 4.98 on Thursday. That’s a 2-day swing of 116% 

Extended Watchlist:
GRTX, MDIA, VSTE, SGRP, MIMO, ENDV, LTNC, MCOM, ITNS

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: Gold Watchlist, Options & More

Tesla Motors Corp. TSLA – Options Update

Our bearish sentiment on TSLA yesterday ended up working in our favor quite well, as the intraday volatility provided traders with not one but three chances to execute lucrative swing trades.  Our specified target range was the TSLA Weekly $200-195 Puts; those three opportunities on the day extended to all three sets of contracts, and were as follows:

$200 Puts – 4.45-8.45 (+55%), 4.15-7.50 (+81%), 4.36-6.35 (+46%)

$197.50 Puts – 4.06-6.35 (+56%), 2.83-5.39 (+90%), 2.83-4.51 (+59%)

$195 Puts – 2.44-5.13 (+110%),1.87-3.81 (+104%), 1.70-2.89 (+70%)

Amid the bombshell that Britain passed a referendum effecting its exit from the European Union (at least a two year process), world markets in general are all feeling the strain at present. TSLA has hit a low of $186 in the premarket, so our observed contracts all stand to produce further gains this morning.

To get ourselves a little closer to the heaviest action in the event of a continued backslide for TSLA, we may consider rolling down our strike range to include the $192.50 and $190 Puts as well.
______

FRESH OPTIONS IDEAS:

As we’ve done many times before when attempting to use overall market conditions to our advantage, we’re going to be tracking some SPY Calls for potential daytrades. As long as the SPY can hold above $200, we could be in line to see some major volatility in the SPY Weekly $200-205 Calls. As always, we must issue a strong note of caution with regard to trading weekly contracts on a Friday. It should only ever be attempted by advanced-level traders!

We also want to submit another familiar face for a potential play with much less urgency. For a longer-term idea, we’ll be putting the PBR 07/15 $6.50 and $7 Calls on our radar.

Gold Watchlist:

We also want to provide our readers with a smattering of gold-related stocks to watch this morning. Currencies are taking a big hit, which usually means an influx of investor confidence in precious metals. As such, we will naturally look to plays like these for quick-hit opportunities:

LODE, PGLC, VGZ, XRA,TRX, GORO

Extended Watchlist:
PXYN, NHMD, DLCR, EMES, ENDV(Bottom bouncer)